-
公开(公告)号:CA2923579A1
公开(公告)日:2015-03-12
申请号:CA2923579
申请日:2014-09-08
Applicant: ACADEMIA SINICA
Inventor: WONG CHI-HUEY , YU ALICE L , LIN KUN-HSIEN , WU TAI-NA
Abstract: Glycosphingolipids (GSLs) bearing a-glucose (a-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with a-glucose (a-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with a-galactose (a-Gal) are disclosed. GSLs bearing a-glucose (a-Glc) and derivatives of a-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with a-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with a-Glc and derivatives thereof are provided.
-
公开(公告)号:DE102012104749B4
公开(公告)日:2015-02-12
申请号:DE102012104749
申请日:2012-06-01
Applicant: ACADEMIA SINICA
Inventor: HWANG ING-SHOU , HWU EN-TE
Abstract: Mehrachsige Aktorvorrichtung für eine Positionierungsvorrichtung, umfassend: ein bewegliches Element; einen Probentisch, der an dem beweglichen Element angebracht ist; eine Mehrzahl von Antriebselementen, die sich in einem reibschlüssigen Eingriff mit dem beweglichen Element befinden und ausgelegt sind, um das bewegliche Element wahlweise entlang einer ersten Richtung zu bewegen; und eine Mehrzahl von Aktoren, die die Mehrzahl von Antriebselementen bewegen, wenn an die Mehrzahl von Aktoren Ansteuersignale angelegt werden, wobei unterschiedliche Ansteuersignale an die Mehrzahl von Aktoren angelegt werden, um unterschiedliche Bewegungen der Antriebselemente zu bewirken, so dass das bewegliche Element unterschiedliche Verschiebungen entlang der Mehrzahl von Antriebselementen ausführt und aufgrund der unterschiedlichen Verschiebung verkippt wird.
-
343.
公开(公告)号:ES2442024T3
公开(公告)日:2014-02-07
申请号:ES09798721
申请日:2009-07-15
Applicant: ACADEMIA SINICA
Inventor: WONG CHI-HUEY , WU CHUNG-YI , TSENG SUSAN Y
Abstract: Una matriz de carbohidratos inmovilizados en un sustrato sólido no transparente revestido con aluminio o unsustrato sólido no transparente revestido con aluminio polifluorado (de tipo politetrafluoroetileno (PTFE)),comprendiendo la matriz: una pluralidad de carbohidratos inmovilizados en localizaciones específicas en una superficie del sustrato sólidono transparente revestido con aluminio, de modo que: (a) los carbohidratos inmovilizados pueden caracterizarse por espectroscopia de masas (EM) y (b) puede realizarse análisis de reacciones de unión entre los carbohidratos y moléculas que se sospechaque se unen específicamente con los carbohidratos, donde el aluminio se usa para revestir un primer sustrato sólido transparente a un grosor mayor de 100 nm paraconvertir el primer sustrato sólido transparente en un sustrato sólido no transparente revestido con aluminio o unsustrato sólido no transparente revestido con aluminio de tipo PTFE polifluorado y donde la superficie del revestimiento de aluminio en el sustrato sólido se anodiza para formar una capa de óxidode aluminio porosa de un grosor menor de 5 nm.
-
公开(公告)号:ZA201101128B
公开(公告)日:2013-11-27
申请号:ZA201101128
申请日:2011-02-11
Applicant: ACADEMIA SINICA
Inventor: WONG CHI-HUEY , YU ALICE , CHANG YA-JEN , LIN KUN-HSIEN , HUNG JUNG-TUNG
IPC: A61K20060101 , A61P20060101
Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.
-
公开(公告)号:NZ597628A
公开(公告)日:2013-07-26
申请号:NZ59762807
申请日:2007-05-11
Applicant: ACADEMIA SINICA , PHARMIGENE INC
Inventor: CHEN YUAN-TSONG , HUNG SHUEN-LU , SHEN CHIH-LUNG , CHANG CHI-FENG , LIN HSIN-YU , CHEN WEI-HSUAN
IPC: C12Q1/68
Abstract: 597628 Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising: Detecting the presence of HLA-B*5801 in a sample obtained from the patient; and Correlating the presence of HLA-B*5801 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxypurinol.
-
公开(公告)号:MX2011009930A
公开(公告)日:2012-05-08
申请号:MX2011009930
申请日:2010-03-26
Applicant: ACADEMIA SINICA
Inventor: WONG CHI-HUEY , MA CHE , WANG CHENG-CHI , CHEN JUINE-RUEY
IPC: A61K39/145 , A61K39/12 , A61K39/155 , A61K39/21 , A61K39/29 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , C07K14/11 , C07K14/135 , C07K14/155 , C07K14/18 , C12P21/02
Abstract: Se proporcionan las composiciones inmunogénicas que comprenden glicoproteínas virales parcialmente glicosiladas para usar como vacunas contra virus. Las vacunas formuladas usando glicoproteínas de superficie viral mono-, di-, o tri- glicosiladas y polipéptidos proporcionan protección potente y amplia contra virus, aún a través de las cepas. Las composiciones farmacéuticas que comprenden polipéptidos de hemaglutinina monoglicosilados y vacunas generadas por los mismos y métodos de su uso para la profilaxis o tratamiento de infecciones virales se describen. Los métodos y composiciones se describen para virus de influenza HA, NA y M2, proteínas F, G y SH RSV, glicoproteínas M o E de virus de Dengue, glicoproteína E1 o E2 de virus de hepatitis C y glicoproteínas gp120 gp41 de VIH.
-
347.
公开(公告)号:NZ572259A
公开(公告)日:2012-03-30
申请号:NZ57225907
申请日:2007-05-11
Applicant: ACADEMIA SINICA , PHARMIGENE INC
Inventor: CHEN YUAN-TSONG , HUNG SHUEN-LU , SHEN CHIH-LUNG , CHANG CHI-FENG , LIN HSIN-YU , CHEN WEI-HSUAN
IPC: C12Q1/68
Abstract: Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising detecting the presence of HLA-B*1502 in a sample obtained from the patient, and correlating the presence of HLA-B*1502 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxcarbazepine.
-
348.
公开(公告)号:HK1153273A1
公开(公告)日:2012-03-23
申请号:HK11107458
申请日:2011-07-18
Applicant: ACADEMIA SINICA
Inventor: WONG CHI-HUEY , WU CHUNG-YI , WANG CHENG-CHI , YU ALICE L
IPC: G01N20060101
Abstract: A cancer diagnostic method using a glycan array that contains Gb5 and Globo H, Bb2, Bb3, and/or Bb4.
-
公开(公告)号:CA2809677A1
公开(公告)日:2012-03-08
申请号:CA2809677
申请日:2011-08-30
Applicant: ACADEMIA SINICA , LIANG CHI MING
Inventor: WU HAN-CHUNG , LU RUEI-MIN
IPC: C07K16/30 , A61K9/14 , A61K39/395 , A61P35/00 , C07K16/28 , C07K17/02 , C12N15/13 , G01N33/574
Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.
-
公开(公告)号:SG173593A1
公开(公告)日:2011-09-29
申请号:SG2011057023
申请日:2010-02-19
Applicant: ACADEMIA SINICA , LIANG CHI MING
Inventor: WU HAN-CHUNG , CHIU CHIEN-YU
Abstract: Cancer-targeting peptides and uses thereof in cancer therapy.
-
-
-
-
-
-
-
-
-